Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

New bifunctional metalloproteinase inhibitors: an integrated approach towards biological improvements and cancer therapy.

Marques SM, Abate CC, Chaves S, Marques F, Santos I, Nuti E, Rossello A, Santos MA.

J Inorg Biochem. 2013 Oct;127:188-202. doi: 10.1016/j.jinorgbio.2013.03.003. Epub 2013 Mar 16.

PMID:
23597851
2.

Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.

Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P.

Bioorg Med Chem. 2013 Nov 1;21(21):6456-65. doi: 10.1016/j.bmc.2013.08.054. Epub 2013 Sep 4.

PMID:
24071448
3.

Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.

Di Pizio A, Laghezza A, Tortorella P, Agamennone M.

ChemMedChem. 2013 Sep;8(9):1475-82, 1421. doi: 10.1002/cmdc.201300186. Epub 2013 Jul 19.

PMID:
23873724
4.

Progress towards water-soluble triazole-based selective MMP-2 inhibitors.

Fabre B, Filipiak K, Zapico JM, Díaz N, Carbajo RJ, Schott AK, Martínez-Alcázar MP, Suárez D, Pineda-Lucena A, Ramos A, de Pascual-Teresa B.

Org Biomol Chem. 2013 Oct 14;11(38):6623-41. doi: 10.1039/c3ob41046c. Epub 2013 Aug 30.

PMID:
23989288
5.

Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group.

Farkas E, Katz Y, Bhusare S, Reich R, Röschenthaler GV, Königsmann M, Breuer E.

J Biol Inorg Chem. 2004 Apr;9(3):307-15. Epub 2004 Feb 5.

PMID:
14762707
6.

Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.

Augé F, Hornebeck W, Decarme M, Laronze JY.

Bioorg Med Chem Lett. 2003 May 19;13(10):1783-6.

PMID:
12729664
8.

Investigating chelating sulfonamides and their use in metalloproteinase inhibitors.

Tanakit A, Rouffet M, Martin DP, Cohen SM.

Dalton Trans. 2012 Jun 7;41(21):6507-15. doi: 10.1039/c2dt12373h. Epub 2012 Mar 12.

9.

Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.

Zhang J, Li X, Jiang Y, Feng J, Li X, Zhang Y, Xu W.

Bioorg Med Chem. 2014 Jun 1;22(11):3055-64. doi: 10.1016/j.bmc.2013.12.025. Epub 2013 Dec 21.

PMID:
24755524
10.

Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.

Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A.

Eur J Med Chem. 2011 Jul;46(7):2617-29. doi: 10.1016/j.ejmech.2011.03.033. Epub 2011 Apr 2.

11.

Cytotoxic activity, X-ray crystal structures and spectroscopic characterization of cobalt(II), copper(II) and zinc(II) coordination compounds with 2-substituted benzimidazoles.

Sánchez-Guadarrama O, López-Sandoval H, Sánchez-Bartéz F, Gracia-Mora I, Höpfl H, Barba-Behrens N.

J Inorg Biochem. 2009 Sep;103(9):1204-13. doi: 10.1016/j.jinorgbio.2009.05.018. Epub 2009 Jun 16.

PMID:
19628280
12.

Design, synthesis and biological evaluation of ferulic Acid amides as selective matrix metalloproteinase inhibitors.

Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA.

Med Chem. 2013 Nov;9(7):947-54.

PMID:
23061601
13.

Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.

Kontogiorgis CA, Papaioannou P, Hadjipavlou-Litina DJ.

Curr Med Chem. 2005;12(3):339-55. Review.

PMID:
15723623
14.

Dicopper(II) and dizinc(II) complexes with nonsymmetric dinucleating ligands based on indolo[3,2-c]quinolines: synthesis, structure, cytotoxicity, and intracellular distribution.

Primik MF, Göschl S, Meier SM, Eberherr N, Jakupec MA, Enyedy É, Novitchi G, Arion VB.

Inorg Chem. 2013 Sep 3;52(17):10137-46. doi: 10.1021/ic401573d. Epub 2013 Aug 16.

15.

A bioinorganic perspective on matrix metalloproteinase inhibition.

Puerta DT, Cohen SM.

Curr Top Med Chem. 2004;4(15):1551-73. Review.

PMID:
15579096
16.

Matrix metalloproteinase inhibitors.

Wojtowicz-Praga SM, Dickson RB, Hawkins MJ.

Invest New Drugs. 1997;15(1):61-75. Review.

PMID:
9195290
17.

Potent "clicked" MMP2 inhibitors: synthesis, molecular modeling and biological exploration.

Zapico JM, Serra P, García-Sanmartín J, Filipiak K, Carbajo RJ, Schott AK, Pineda-Lucena A, Martínez A, Martín-Santamaría S, de Pascual-Teresa B, Ramos A.

Org Biomol Chem. 2011 Jun 21;9(12):4587-99. doi: 10.1039/c0ob00852d. Epub 2011 May 6.

PMID:
21552627
18.

Antitumor effects of a tetradentate amido-carboxylate ligands and corresponding square-planar palladium(II) complexes toward some cancer cells. Crystal structure, DFT modeling and ligand to DNA probe docking simulation.

Matović ZD, Mrkalić E, Bogdanović G, Kojić V, Meetsma A, Jelić R.

J Inorg Biochem. 2013 Apr;121:134-44. doi: 10.1016/j.jinorgbio.2013.01.006. Epub 2013 Jan 16.

PMID:
23376555
19.

A macrophage cell model for selective metalloproteinase inhibitor design.

Jacobsen FE, Buczynski MW, Dennis EA, Cohen SM.

Chembiochem. 2008 Sep 1;9(13):2087-95. doi: 10.1002/cbic.200800148.

20.

New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.

Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G.

Bioorg Med Chem. 2015 Jul 1;23(13):3809-18. doi: 10.1016/j.bmc.2015.03.078. Epub 2015 Apr 6.

PMID:
25921268
Items per page

Supplemental Content

Write to the Help Desk